Francesco Burzotta HOTLINE III, ESC Congress 2007 September 4th 2007, Vienna OPTIMIST: the Outcome of Pci for stent-ThrombosIs MultIcentre STudy Institute.

Slides:



Advertisements
Similar presentations
Decline in the Use of Drug-Eluting Stents for Patients With NSTEMI Undergoing PCI: Results From the CRUSADE and ACTION Registries Matthew T. Roe, Christopher.
Advertisements

BIFURCATION LESIONS Dr. Tahsin.N
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Can we prevent stent restenosis after coronary stent implantation
on behalf of the TOTAL Investigators
TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Unrestricted Use of Drug-Eluting Stents Compared with Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood.
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Female Gender Is An Independent Predictor Of In-Hospital Mortality After STEMI In The Era of Primary PCI. Insights From The Greater Paris Area PCI Registry.
1 SIROLIMUS-ELUTING STENTS FOR IN-STENT RESTENOSIS TREATMENT IN 278 UNSELECTED PATIENTS: INSIGHTS ON LONG-TERM OUTCOMES FROM A LARGE TWO-CENTER REGISTRY.
ATTEMPT study: pooled-Analysis of Trials on ThrombEctomy in acute Myocardial infarction based on individual PatienT data CLINICAL TRIAL UPDATE III ESC.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
TCT 2009 Stent Thrombosis Following Primary PCI in STEMI: Predictors, Clinical Impact and Preventive Strategies from the Horizons AMI Trial George D. Dangas,
Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts Laura Mauri, MD, MSc; Treacy Silverstein, B.Sc.; Ann Lovett,
Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.
Maurizio Menichelli MD San Camillo Hospital, Rome ( SESAMI Trial) Maurizio Menichelli Presenter Disclosure Information Nothing to Disclose Randomized trial.
Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.
RESEARCH, REDUCE III, X-AMINE ST, COOL-MI Azfar Zaman Freeman Hospital, Newcastle.
TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.
PJ Devereaux, Population Health Research Institute, Hamilton, Canada on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
CARDIOLOGIA INV 1 CAREGGI - FIRENZE Objective To determine whether nonresponsiveness to clopidogrel as revealed by high in vitro residual platelet reactivity.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.
Real-world clinical experience with an everolimus eluting platinum chromium stent with an abluminal biodegradable polymer – a report from the Swedish Coronary.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.
Latvian Centre of Cardiology real-life registry
The BVS-SAVE Italian registry: Bioresorbable Vascular Scaffolds
results from the Italian multicentre RAI Registry
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,
Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,
American College of Cardiology Presented by Dr. Stephan Windecker
REALITY: 8 month results
3-Year Clinical Outcomes From the RESOLUTE US Study
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
The American College of Cardiology Presented by Dr. Raimund Erbel
Impact of Platelet Reactivity Following Clopidogrel Administration
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
European Society of Cardiology Scientific Congress, September 2006
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Impact of Diabetes Mellitus on Long-term Outcomes in the
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

Francesco Burzotta HOTLINE III, ESC Congress 2007 September 4th 2007, Vienna OPTIMIST: the Outcome of Pci for stent-ThrombosIs MultIcentre STudy Institute of Cardiology, Policlinico A. Gemelli – Catholic University of the Sacred Heart (UCSC)

BACKGROUND AND RATIONALE FOR THE STUDY Stent thrombosis occurs in 1-2% of the pts treated by PCI with stent implantation Usage of drug-eluting stents (DES) in the real world practice might increase risk of stent thrombosis compared to bare metal stents (BMS) The most common management of pts with stent thrombosis is re-PCI There is lack of scientific data describing the angiographic and clinical outcome of PCI for stent thrombosis in the contemporary DES era

AIMS OF THE OPTIMIST STUDY TO COMPARE THE CLINICAL AND ANGIOGRAPHIC CHARACTERISTICS OF DES VS BMS THROMBOSIS TO EVALUATE THE EFFICACY OF THROMBECTOMY DEVICES DURING PCI FOR STENT THROMBOSIS TO ASSESS THE CLINICAL OUTCOME OF PCI FOR STENT THROMBOSIS

THE OPTIMIST STUDY DESIGN Non sponsored, multicentre registry S.Pietro FBF (Dr Belloni) S.Filippo Neri (Dr Pristipino) Pol. Gemelli (Prof. Crea, Dr Trani, Dr Romagnoli) S.Camillo (Dr Parma) S.Spirito (Dr Danesi) S.Eugenio (Dr Gioffrè) Pol. Umberto I (Dr Sardella) Pertini (Dr Rigattieri) Pol. Casilino (Dr Summaria) S.Carlo (Dr Mazzarotto) S.Giovanni (Dr. Manzoli)

Non sponsored, multicentre registry Burzotta et al, Am Heart J 2007 Enrolling during two years ( ) all patients undergoing urgent PCI for angiographically-confirmed stent thrombosis The clinical 30-day 6-month (primary endpoints: death and MACCE) The angiographic outcome of PCI by an independent core-lab: Rome Heart Research, Dr Prati (primary end-points: TIMI 3+MBG 2-3 and MBG 3) TO ASSESS: THE OPTIMIST STUDY DESIGN

RESULTS PREVALENCE OF PCI FOR STENT THROMBOSIS

12280* PCI with stenting 7318* PCI with DES (59.6%) OPTIMIST centres 4962* PCI with BMS (40.4%) *Official data of the Italian Society of Interventional Cardiology SICI-GISE 120 PCI for stent thrombosis in 110 patients 62 PCI for DES thrombosis 52 PCI for BMS thrombosis = = 0.85% 1.05% P= * urgent (primary or rescue) PCI for STEMI 89 (74%) STEMI NSTEMI UA = 3.6%

CHARACTERISTICS OF THE STUDY POPULATION Characteristics Males70% Age (yrs, mean+SD)66+12 Diabetes30% Renal Failure20% Anti-PTL therapy withdrawal <15 days10% Symptoms-to-PCI time (hrs, mean+SD) Cardiogenic Shock17% Type of thrombosed stent DES (SES, PES, other) BMS Unknown 50% (26%,14%,7%) 38% 12% Interval between PCI and stent thrombosis (days, mean+SD) Left anterior descending artery (LAD)50% Pre-PCI TIMI 0-184%

DES vs BMS THROMBOSIS RESULTS

CharacteristicsDES (n=55) BMS (n=43) P Age (yrs+SD) Diabetes40%19%0.02 Anti-PLT therapy withdrawal <15 days 15%2%0.04 LAD66%37%<0.001 Bifurcation27%7%0.01 Stent diameter DES VS BMS: BASELINE CHARACTERISTICS

CharacteristicsDES (n=55) BMS (n=43) P Age (yrs+SD) Diabetes40%19%0.02 Anti-PLT therapy withdrawal <15 days 15%2%0.04 LAD66%37%<0.001 Bifurcation27%7%0.01 Stent diameter DES VS BMS: BASELINE CHARACTERISTICS

1-30 days0-24 hrs> 1 year days ACUTESUBACUTELATEVERY LATE % DES BMS DES VS BMS: TYPES OF THROMBOSIS

DES BMS <30 days> 30 days LATE or VERY LATE % P=0.03 ACUTE or SUBACUTE DES VS BMS: TYPES OF THROMBOSIS

OUTCOME OF PCI FOR STENT THROMBOSIS RESULTS

PROCEDURAL CHARACTERISTICS PCI STRATEGY Balloon dilation95% Thrombectomy30% Stent implantation -DES -BMS 45% 20% 25% ANGIOGRAPHIC OUTCOME TIMI 3 TIMI 2 TIMI % 15% 12% Residual Stenosis (mean+SD)18+26% MBG 3 MBG 2 MBG % 27% 24%

PCI FOR STENT THROMBOSIS: CLINICAL OUTCOME 30-day6-month Death12%16% Non-fatal Mycardial infarction7%11% Target Lesion Revasc.13%17% Stroke1% MACCE21%29%

DES VS BMS: OUTCOME AFTER THROMBOSIS DES BMS no death no MACCE % mo.6 mo.12 mo.

OR (95%CI) for 6-month mortality in MULTIVARIATE analysis PREDICTORS OF OUTCOME IN PCI FOR STENT THROMBOSIS VERY LATE THROMBOSIS 10.0 ( ) OTHER IMPLANTED STENT DURING PCI 5.4 ( ) POST-PCI MBG ( ) increased mortality

THROMBECTOMY DURING PCI FOR STENT THROMBOSIS RESULTS

BY INTENTION TO TREAT PCI FOR STENT THROMBOSIS: USE OF THROMBECTOMY Selection of devices according to the operator’s preference STANDARD PCI in 83 pts (75%) THROMBECTOMY in 27 PTS (25%) > Longer time-to-treatment > Females > STEMI > Inotropic drugs pre-PCI pre-PCI risk features > Large vessels Angiojet Angiojet (7,5%) Diver CE Diver CE (48.1%) Export Export (44.4%)

ANGIOGRAPHIC RESULTS OF THROMBECTOMY TIMI 3 + MBG 2/3MBG 3Thrombectomy Standard PCI % 76% 61% 52% 46% Pts without Shock (n=81) % 89% 61% 46% P=0.027P=0.18

CONCLUSIONS 1. Urgent PCI is needed for both DES and BMS thrombosis and represents 3.6% of the urgent PCI for STEMI 2. PCI for stent thrombosis is associated with a high rate of major adverse events, especially in pts with very late thrombosis 3. DES thrombosis, compared to BMS, shows different clinical features (late or very late presentation, association with anti-PLT therapy withdrawal) but similar long term outcome 4. During PCI for stent thrombosis, implantation of other stents should be avoided. Mechanical thrombectomy is feasible and should be reserved to pts without haemodynamic instability In the contemporary DES era…

Thank you for your attention